Garuda - Garba Rujukan Digital

Article Per Year (5 Year)

All

Indonesian Journal of Cancer

ijoc
Website

Published by National Cancer Center-Dharmais Cancer Hospital

ISSN : 19783744 EISSN : 23556811 DOI : https://www.doi.org/ 10.33371

Core Subject : Health, Science,

Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Public Health

Indonesian Journal of Cancer is a peer-reviewed and open-access journal. This journal is published quarterly (in March, June, September, and December) by Dharmais Cancer Hospital - National Cancer Center. Submissions are reviewed under a broad scope of topics relevant to experimental and clinical cancer research. Articles are original research that needs to be disseminated and written in English. All submitted manuscripts will go through the double-blind peer review and editorial review before being granted acceptance for publication. The journal publishes original research articles, case reports, and review articles under the following categories: cancer management, cancer prevention, cancer etiology, epidemiology, molecular oncology, cancer diagnosis and therapy, tumor pathology, surgical oncology, medical oncology, radiation oncology, interventional radiology, as well as early detection.

Arjuna Subject : Kedokteran - Onkologi

Articles 562 Documents

21 22 23 24 25

Program Psikososial di Bangsal Kanker Anak Rumah Sakit Kanker "Dharmais" Edi Setiawan Tehuteru; Raden Citra Kusumarojo
Indonesian Journal of Cancer Vol 1, No 1 (2007): Jan - Mar 2007
Publisher : National Cancer Center - Dharmais Cancer Hospital

Sekalipun sakit, seorang anak yang sedang dalam pengobatan tetap harus diperhatikan masalah tumbuh kembangnya. Guna memenuhi tuntutan ini, Bangsal Kanker Anak RS Kanker "Dharmais" menggunakan pendekatan psikososial selain dari pendekatan medis tentunya. Diharapkan pendekatan ini mampu memfasilitasi proses tumbuh kembang anak-anak yang mengalami kanker dan harus dirawat untuk waktu yang cukup lama. Tujuan penulisan kasus ini adalah untuk memperlihatkan program psikososial yang dilakukan di RS Kanker "Dharmais".Program psikososial mulai dilakukankan bulan Juli 2006 oleh relawan yang tergabung dalam Community for Children with Cancer. Program-programnya terdiri dari pemberian informasi tentang penyakit dan pengobatan kanker pada anak kepada pasien dan keluarganya, pendampingan saat proses diagnostik dan pengobatan berlangsung, membuat kegiatan untuk pasien seperti playground activity, art therapy, school in hospital, bed side art therapy, dan computer therapy. Kegiatan yang ada menyebabkan anak tidak takut menjalani pengobatan dan memungkinkan mereka untuk tetap dapat bermain layaknya anak-anak yang sehat.Hasil dari pendekatan ini memungkinkan anak ditangani secara holistik dan yang terpenting program ini dapat memfasilitasi proses tumbuh kembang mereka.

Evaluation of Kidney Injury Molecule-1 (KIM-1) and Neutrophil Gelatinase-Associated Lipocalin (NGAL) Urinary Levels for Detecting Kidney Dysfunction in Patients With Nasopharyngeal Cancer Treated With Cisplatin-Based Treatment Marliana Sri Rejeki; Wawaimuli Arozal; Rianto Setiabudy; Djumhana Atmakusuma
Indonesian Journal of Cancer Vol 12, No 2 (2018): April-June
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Cisplatin has a potency of causing nephrotoxicity. Serum BUN and creatinine levels have been well-known for detecting kidney dysfunction; while KIM-1 and NGAL urine levels are relatively new measurements. The study was aimed to evaluate urinary KIM-1 and NGAL level to detect kidney dysfunction in patients with advanced stage NPC who received cisplatin-based chemotherapy.Methods: The study was a cohort-prospective study with 3 subject groups, i.e. patients who had never received and who had received 75-100 mg/m2 cisplatin-based chemotherapy as well as those who had never received 40 mg/m2 cisplatin-based chemotherapy. The levels of urinary KIM-1, NGAL and serum level of BUN and creatinine were measured before and after receiving cisplatin. Statistical analyses were ANOVA, Pearson, Spearman, Kolmogorov-Smirnov test and SPSS version 22.0.Result: There was a significant difference of delta BUN level (p=0.0001) and delta urinary NGAL level (p = 0.025) before and after treatment in all three groups; while delta KIM-1 level showed no significant difference in all three groups (p=0.275). Cisplatin may cause accumulated nephrotoxicity, which has dose-dependent manner.Conclusion: Measuring urinary NGAL level can detect an early stage of kidney dysfunction; however, it still cannot replace the role of BUN. Measurement of urinary KIM-1 level cannot detect kidney dysfunction.

A Rare and Fatal Case of Cutaneous T-Cell Lymphoma (CTCL) Lia Sasmithae; Indra Perdana
Indonesian Journal of Cancer Vol 15, No 3 (2021): September
Publisher : National Cancer Center - Dharmais Cancer Hospital

Introduction: Cutaneous T-Cell Lymphoma (CTCL) is a form of Non-Hodgkin Lymphoma involving T-cell neoplasms mainly concentrated in the skin. Primary Cutaneous Peripheral T-Cell Lymphoma is Not Otherwise Specified (PTL-NOS) is the rarest case of CTCL disease.Case Presentation: A female, 35 years old, complained of a lump on her face. In the last 3 months, the lump felt soft, contained a liquid that, when it ruptures, secretes Blood, and the crusty scar will blacken and easily bleed with pain. Physical examination of pale conjunctiva on the face, neck, chest, abdomen, back, and legs obtained nodules with a chewy consistency with erythema appearance in varying size. Some nodules that appear were covered in blackish crustae. The right lung has a decrease in the sound of breath, accompanied by swelling in both limbs. The conclusion of bilateral femur skin biopsy impresses cutaneous T lymphoma cells. Within three months, cancer developed into lesions spread almost throughout the body, and due to the rapid and progressive nature of cancer, its diagnosis developed into PTL-NOS.Conclusions: Patients with PTL-NOS may come with solitary nodules such as red tumors in any area of the body. However, most often, patients come with symptoms of multifocal or diffuse scattered nodules. In enforcing the diagnosis, it takes a high level of suspicion, and multiple rebiopsies are necessary to enforce the diagnosis of CTCL.

Profil Jantung Pasien Akut Limfoblastik Leukemia Anak yang Mendapatkan Terapi Anthracycline DAVID VICTORY WA’U; SRI MULATSIH; INDAH KARTIKA MURNI
Indonesian Journal of Cancer Vol 11, No 1 (2017): Jan-Mar
Publisher : National Cancer Center - Dharmais Cancer Hospital

ABSTRACTAcute lymphoblastic leukemia (ALL) is the most common malignancy in children under fifteen years of age. Advanced cancer therapy with anthracycline has increased survival rate but also chronic health problem and the most iscardiovascular. This study aims to describe cardiac events of ALL patients who received anthracyline during chemotherapy. We conducted a cross sectional study of childhood ALL who were hospitalized at DR Sardjito hospital between April and June 2016. Electrocardiography (ECG) and echocardiography were performed. Results of this study shows childhood ALL who received anthracycline may suffer from cardiotoxicity. Cardiac events can be found in all stage of chemotherapy.ABSTRAKLeukemia limfoblastik akut (LLA) adalah keganasan yang paling banyak dialami anak di bawah usia 15 tahun. Kemajuan pengobatan kanker dengan anthracycline telah meningkatkan angka kesintasan penderita LLA dan masalah kesehatan kronik, terutama penyakit kardiovaskuler. Penelitian ini bertujuan untuk mengetahui kelainan jantung pada pasien LLA yang mendapatkan kemoterapi anthracyline. Penelitian dilakukan secara potong lintang dengan subjek anak penderita LLA yang dirawat di rumah sakit Dr. Sardjito antara April–Juni 2016. Pasien menjalani pemeriksaan elektrokardiografi (EKG) dan echocardiography. Penelitian ini menyimpulkan bahwa anak penderita ALL yang mendapatkan anthracycline dapat mengalami kardiotoksisitas. Kelainan jantung dapat ditemukan pada semua tahap kemoterapi.

Sepsis in Children with Acute Lymphoblastic Leukemia Mururul Aisyi; Fifi Dwijayanti; Reni Wigati; Haridini Intan Mahdi; Laswita Yunus; Chainurridha Chainurridha; Tri Aprilliana Wulandari
Indonesian Journal of Cancer Vol 14, No 4 (2020): December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Sepsis is the leading cause of morbidity and mortality in children worldwide, with around 75,000 inpatients each year and nearly 50% dying in pediatric hospitals. Acute lymphoblastic leukemia (ALL) in childhood is a malignancy originating from lymphoid progenitor cells, usually at the age of 2–6 years. Children with ALL contribute 30% to childhood cancer cases under 15 years old. Sepsis in pediatric patients increases mortality significantly. A previous study showed that the prevalence of sepsis in pediatrics is still high. Thus, this study aims to report ALL patients with sepsis in our institution.Methods: This study was a descriptive cross-sectional study at the National Cancer Center (NCC) - Dharmais Cancer Hospital. We recruited acute lymphoblastic leukemia (ALL) patients aged 2-18 years with suspected or documented sepsis based on Systemic Inflammatory Response Syndrome (SIRS) by The International Consensus Conference on Pediatric Sepsis. The data were collected by medical records from January 2014 to December 2018.Results: A total of 94 pediatric patients in the study included 57 males and 37 females with an average age of 5 years. The age range was 1–18 years with a median age of 5 years. The prevalence of sepsis in pediatric with ALL was 11 patients (11.7%) and 45.5% of deaths. The clinical conditions were as follows: abnormal temperature (8 [72.7%]), abnormal blood pressure, systolic (7 [63.6%]) and diastolic (7 [63.6%]), abnormal pulse rate (9 [81.8%]), abnormal respiratory rate (8 [72.7%]), and normal saturation (6 [54.5%]). We also did a laboratory check followed by all sepsis patients who had abnormal leukocytes (11 [100%]), and abnormal lymphocytes count (8 [72.7%]).Conclusions: The mortality rate and prevalence of sepsis in children with ALL in our institution are still high. Further prospective studies are required to explore the risk factors and predictors of sepsis based on its severity and adherence of health workers to implement guidelines on patients with sepsis in the hospital.

Pengaruh Ketidakhomogenan Medium pada Radioterapi SUPRIYANTO A. PAWIRO; SUGIYANTARI -; TIRTO WAHONO
Indonesian Journal of Cancer Vol 3, No 1 (2009): Jan - Mar 2009
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v3i1.65

Telah dilakukan pengukuran Percentage Depth Dose (PDD) pada medium homogen dan nonhomogen dengan menggunakan bilik ionisasi plan paralel Markus. Phantom homogen dibuat dari susunan lapisan akrilik setebal 30 cm, dan phantom nonhomogen dibuat dengan menyisipkan lapisan gabus ekivalen paru-paru setebal 4 cm yang dimasukkan ke dalam susunan akrilik. Penyinaran dilakukan dengan sinar-X 6 MV dan 10 MV yang diproduksi oleh LINAC Varian 2100C. Perbedaan prosentase dosis kedalaman (PDD) pada medium homogen dan nonhomogen rata-rata sebesar 4,3% pada sinar-X 6 MV dan 3,7% pada sinar-X 10 MV. Pemberian gabus pada akrilik mengakibatkan peningkatan dosis sampai 11,7% pada sinar-X 6 MV dan 10,2% pada sinar-X 10 MV. Faktor koreksi yang dihasilkan sebagai akibat adanya material ekivalen paru-paru/gabus mencapai 1,19 pada sinar-X 6 MV dan 1,15 pada sinar-X 10 MV.Kata kunci: Medium tak homogen, Markus chamber, faktor koreksi

Tren Tata Laksana Kanker Prostat Lokal Lanjut di Indonesia GAMPO ALAM IRDAM
Indonesian Journal of Cancer Vol 9, No 1 (2015): Jan - Mar 2015
Publisher : National Cancer Center - Dharmais Cancer Hospital

ABSTRACTAim: to evaluate treatment trend of stage T3 prostate cancer based on several factors. Methods: a retrospective studywas done on stage T3 prostate cancer patients from year 1995-2013, at two national referral hospitalsin Indonesia.Treatment trends between hormonal therapy and radiotherapy based on year of treatment, PSA level, tumor grade andage groups were evaluated.Results: On 50 patients subjects, 25 (50%), 23 (46%) and 2 (4%) subjects were treated byradiotherapy, hormonal therapy and radical prostatectomy, respectively. Year of treatment were significantly associatedwith treatment selection (p=0.012), after excluding year of treatment 1995-1999 group. Hormonal therapy was preferredon high grade tumor group (53.8%) and more applied for older patients. Treatment trend was not affected by PSA level.Conclusion: Year of treatment were significantly associated with treatment selection of stage T3 prostate cancer.Hormonal therapy was preferred on high grade tumor group and older age groups.Keyword: treatment trend, locally advanced prostate cancer, radiotherapy, hormonal therapyABSTRAKPenelitian ini bertujuan mengevaluasi tren tata laksana kanker prostat stage T3 berdasarkan faktor-faktor yangmemengaruhi. Metode: studi retrospektif tata laksana kanker prostat stage T3 di Rumah Sakit Cipto Mangunkusumodan Rumah Sakit Kanker Dharmais periode 1995-2013. Data tren pemilihan terapi antara radioterapi atau terapihormonal dianalisis berdasarkan kelompok tahun terapi, kadar PSA, grade tumor, dan kelompok usia. Hasil penelitianmenunjukkan dari 50 subjek, 25 (50%), 23 (46%), dan 2 (4%) subjek mendapatkan tata laksana radioterapi, terapihormonal, dan prostatektomi radikal secara berturutan. Perubahan tren pemilihan terapi berdasarkan tahun terapisecara statistik signifikan (p=0,012), dengan mengeksklusikan kelompok periode terapi 1995-1999. Terapi hormonallebih menjadi pilihan untuk kelompok tumor high grade (53,8%) dan lebih sering dipilih seiring bertambahnya usiapasien. Kadar PSA tidak memengaruhi tren pemilihan terapi. Kesimpulan: terdapat perubahan yang bermakna dalampemilihan terapi kanker prostat stage T3 berdasarkan tahun terapi. Terapi hormonal lebih menjadi pilihan pada kasusdengan tumor high grade dan kelompok usia yang semakin tua.Kata Kunci: tren terapi, kanker prostat lokal lanjut, radioterapi, terapi hormonal

Preliminary Report: Clinical Characteristic, Hematologic Response and Gene Mutation of Patients with Chronic Phase Chronic Myeloid Leukemia (CML) to Imatinib at Cipto Mangunkusumo National Hospital (RSUPN CM) Arif Harryanto Reksodiputro; Hilman Tadjoedin; Ikhwan Rinaldi
Indonesian Journal of Cancer Vol 5, No 4 (2011): Oct - Dec 2011
Publisher : National Cancer Center - Dharmais Cancer Hospital

Leukemia Granulositik Kronik (LGK) disebabkan oleh gen BCR-Abl domaintyrosin kinase, produk dari kromosom Philadelphia. Imatinib mesylate merupakan inhibitor selektif terhadap kinase tersebut. Di Indonesia, data mengenai karakteristik pasien LGK fase kronik, respons hematologi terhadap imatinib, dan mutasi gen masih jarang ditemukan. Metode dan desain: studi potong lintang ini menggunakan data rekam medik pasien yang didiagnosis sebagai LGK fase kronik dengan BCR-ABL positif yang berobat ke Poliklinik Teratai Departemen Ilmu Penyakit Dalam Rumah Sakit Cipto Mangunkusumo selama Januari Desember 2009.Hasil: dalam periode 1 tahun studi, peneliti mengikutsertakan 20 pasien LGK fase kronik yang memiliki BCR-ABL positif dengan median umur 36 tahun (13-62 tahun). Pasien laki-laki lebih banyak dibandingkan dengan perempuan (12 vs 7) dengan rasio 1,7: 1. Sebanyak tujuh pasien (36,8%) berasal dari suku Jawa. Dilaporkan juga karakteristik pasien adalah 15 orang berada pada fase kronik (78,9%); 3 pasien berada pada fase akselerasi (15,8%) sementara 1 pasien mengalami krisis blast (5,3%); 12 pasien (63,2%) ditemui adanya splenomegali; dan 5 dari 11 pasien dilaporkan memiliki skor Sokal yang rendah. Berdasarkan hasil laboratorium didapati nilai median hemoglobin 9,9 g/dL (5-14 g/dL); leukosit 73.000/uL (4.100-332.000/uL) dan nilai median trombosit 481.000/uL (263.000/uL-1.116.000/uL); nilai median kadar basofil di darah perifer 1% (1-10%) dengan nilai median sel blast di perifer adalah 1% (0-22%). Selama studi, respons hematologik komplet dalam 3 bulan dicapai oleh 10 dari 19 pasien (52,6%), termasuk di antaranya 1 pasien yang mengalami fase akselerasi dan 1 pasien yang lain mengalami krisis blast. Sebanyak 18 pasien (94,7%) telah diobati dengan hydrea sebelum mendapat terapi Imatinib, sementara 1 pasien (5,3%) tidak pernah mendapatkan pengobatan apapun sebelumnya.Kesimpulan: didapati nilai median usia pasien LGK fase kronik adalah 36 tahun, sebagian besar adalah laki-laki. Sebanyak enam puluh tiga persen pasien memiliki splenomegali. Dilaporkan juga nilai median leukosit adalah 73.000/uL (4.100-332.000/uL) dengan nilai median sel blast di darah perifer sebanyak 1% (0-22%). Respons hematologik komplet dalam 3 bulan dicapai oleh 52,6% pasien.Kata kunci: LGK fase kronik, imatinib, respons hematologik, mutasi.

Cancer Immunology: From Immunosurveillance to Immunoescape Siti Boedina Kresno
Indonesian Journal of Cancer Vol 2, No 1 (2008): Jan - Mar 2008
Publisher : National Cancer Center - Dharmais Cancer Hospital

Sejak lama telah diketahui bahwa sistem imun dapat mengidentifikasi dan menyingkirkan sel tumor berdasarkan ekspresi antigen tumor atau molekul yang diinduksi oleh stres pada sel. Proses ini dikenal sebagai tumor immunosurveillance, pada proses mana sistem imun mengidentifikasi sel kanker dan sel prekanker kemudian menghancurkannya sebelum sel itu menjadi berbahaya. Berbagai sel efektor, seperti sel B, T, NK, NKT, IFN, perforin dan granzyme telah sejak lama diketahui secara jelas peranannya dalam immunosurveillance. Walaupun telah jelas bahwa ada immunosurveillance dan sel kanker dapat dikenal dan dihancurkan oleh sistem imun, mengapa kanker masih tetap dapat tumbuh dan berkembang pada orang yang imunokompeten? Berbagai penelitian telah membuktikan bahwa immunosurveillance hanyalah salah satu dimensi dari hubungan yang kompleks antara tumor dengan sistem imun. Juga telah banyak bukti bahwa sistem imun dapat merangsang munculnya tumor dengan imunogenesitas rendah yang mampu menghindar dari penghancuran oleh sistem imun. Penemuan ini mengakibatkan berkembangnya hipotesis baru yang dikenal sebagai hipotesis immunoediting.Tinjauan pustaka ini akan merangkum interaksi antara pejamu dengan sel-sel tumor yang berakibat eliminasi, ekilibrium clan escape, yang dikenal dengan istilah 3E dari proses immunoediting.

Penanganan Terkini Metastasis Kelenjar Getah Bening pada Karsinoma Sel Skuamus (KSS) Penis MOCHAMMAD REZA ARIEF RAKHMAN; RAINY UMBAS
Indonesian Journal of Cancer Vol 8, No 1 (2014): Jan - Mar 2014
Publisher : National Cancer Center - Dharmais Cancer Hospital

Recently, the incidence of penile cancer were increased. Two tertier hospital in Jakarta reporting an escalation in the average penile cancer patients from 1,8 to 6,2 per year in the last 16 years (1988-2005). The incidence of regional lymph node metastases was affected by the tumour grading. Only 2 out of 47 cases (4%) in Tis or Ta, 5 out of 73 cases in pT1 (G1/G1-2) and 9 out of 24 cases (38%) in pT1 (G2). 59% inguinal metastase was discovered in pT2. 5 years survival rate was 95% in negative lymphatic nodes, 76% in positive lymphatic node and 0% when pelvic metastatic was found.This study provides information about recent treatments for lymph node metastase in penile squamus cell carcinoma (SCC). Treatment for regional lymph node metastase by NCCN guidelines depends on tumour grade, palpability, nodul size, mobility, unilateral or bilateral. The treatment itself can be surgical (ILND,PLND), radiotherapy and chemotherapy

Page 23 of 57 | Total Record : 562

21 22 23 24 25

Filter by Year

2007 2025

Filter By Issues

All Issue Vol 19, No 3 (2025): September Vol 19, No 2 (2025): June Vol 19, No 1 (2025): March Vol 18, No 4 (2024): December Vol 18, No 3 (2024): September Vol 18, No 2 (2024): June Vol 18, No 1 (2024): March Vol 17, No 4 (2023): December Vol 17, No 3 (2023): September Vol 17, No 2 (2023): June Vol 17, No 1 (2023): March Vol 16, No 4 (2022): December Vol 16, No 3 (2022): September Vol 16, No 2 (2022): June Vol 16, No 1 (2022): March Vol 15, No 4 (2021): December Vol 15, No 3 (2021): September Vol 15, No 2 (2021): June Vol 15, No 1 (2021): March Vol 14, No 4 (2020): December Vol 14, No 3 (2020): September Vol 14, No 2 (2020): June Vol 14, No 1 (2020): March Vol 13, No 4 (2019): December Vol 13, No 3 (2019): September Vol 13, No 2 (2019): June Vol 13, No 1 (2019): March Vol 12, No 4 (2018): October-December Vol 12, No 3 (2018): July-September Vol 12, No 2 (2018): April-June Vol 12, No 1 (2018): Jan - Mar Vol 11, No 4 (2017): October- December 2017 Vol 11, No 3 (2017): July - September 2017 Vol 11, No 2 (2017): April - June Vol 11, No 1 (2017): Jan-Mar Vol 10, No 4 (2016): October - December 2016 Vol 10, No 3 (2016): July - September 2016 Vol 10, No 2 (2016): April - June 2016 Vol 10, No 1 (2016): Jan - Mar 2016 Vol 9, No 4 (2015): Okt - Des 2015 Vol 9, No 3 (2015): Jul - Sept 2015 Vol 9, No 2 (2015): April-Juni 2015 Vol 9, No 1 (2015): Jan - Mar 2015 Vol 8, No 4 (2014): Oct - Dec 2014 Vol 8, No 3 (2014): Jul - Sep 2014 Vol 8, No 2 (2014): April-Juni 2014 Vol 8, No 1 (2014): Jan - Mar 2014 Vol 7, No 4 (2013): Oct - Dec 2013 Vol 7, No 3 (2013): Jul - Sep 2013 Vol 7, No 2 (2013): Apr - Jun 2013 Vol 7, No 1 (2013): Jan - Mar 2013 Vol 6, No 4 (2012): Oct - Dec 2012 Vol 6, No 3 (2012): Jul - Sep 2012 Vol 6, No 2 (2012): Apr - Jun 2012 Vol 6, No 1 (2012): Jan - Mar 2012 Vol 5, No 4 (2011): Oct - Dec 2011 Vol 5, No 3 (2011): Jul - Sep 2011 Vol 5, No 2 (2011): Apr - Jun 2011 Vol 5, No 1 (2011): Jan - Mar 2011 Vol 4, No 4 (2010): Oct - Dec 2010 Vol 4, No 3 (2010): Jul - Sep 2010 Vol 4, No 2 (2010): Apr - Jun 2010 Vol 4, No 1 (2010): Jan - Mar 2010 Vol 3, No 4 (2009): Oct - Dec 2009 Vol 3, No 3 (2009): Jul - Sep 2009 Vol 3, No 2 (2009): Apr - Jun 2009 Vol 3, No 1 (2009): Jan - Mar 2009 Vol 2, No 4 (2008): Oct - Dec 2008 Vol 2, No 3 (2008): Jul - Sep 2008 Vol 2, No 2 (2008): Apr - Jun 2008 Vol 2, No 1 (2008): Jan - Mar 2008 Vol 1, No 4 (2007): Oct - Dec 2007 Vol 1, No 3 (2007): Jul - Sep 2007 Vol 1, No 2 (2007): Apr - Jun 2007 Vol 1, No 1 (2007): Jan - Mar 2007 More Issue

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name
Bayu Brahma

Contact Email
journal.cancer@gmail.com

Phone
+628176389956

Journal Mail Official
admin@indonesianjournalofcancer.or.id

Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location
Kota adm. jakarta barat,

Dki jakarta

INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name Bayu Brahma

Contact Email journal.cancer@gmail.com

Phone +628176389956

Journal Mail Official admin@indonesianjournalofcancer.or.id

Editorial Address National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location Kota adm. jakarta barat, Dki jakarta INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Contact Name
Bayu Brahma

Contact Email
journal.cancer@gmail.com

Phone
+628176389956

Journal Mail Official
admin@indonesianjournalofcancer.or.id

Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location
Kota adm. jakarta barat,

Dki jakarta

INDONESIA